Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011

Posted:
9
September 2011

Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011 at the Crowne Plaza Chicago O'Hare Hotel. This years meeting promises to be an exciting event that will hosting a series of excellent workshops and symposia on current, relevant topics related to improving the optimal development and use of therapeutics, with a specific focus on clinical pharmacology.Richmond Pharmacologys CEO and co-founder Dr Jorg Taubel is due to present on Monday 12th September from 18h00 to 20h00, covering the following topics of discussion:

  • Alternative Methods for The Confirmation Of Assay Sensitivity In Thorough QT Studies
  • The Use of Non-invasive Blood Pressure Recording By Photoplethysmography In Early Phase Clinical Trial Studies

Furthermore, Richmond Pharmacology will be exhibiting at the meeting, if you plan to attend we welcome you to come see us at booth number 3 to learn more about our service offering and how our specialist expertise can enhance your next clinical study. If you would like to arrange a face to face meeting with Dr Taubel, please contact a member of our business development team to arrange a time at your convenience.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more